4.4 Review

Long noncoding RNAs: A new player in the prevention and treatment of diabetic cardiomyopathy?

Journal

DIABETES-METABOLISM RESEARCH AND REVIEWS
Volume 34, Issue 8, Pages -

Publisher

WILEY
DOI: 10.1002/dmrr.3056

Keywords

diabetic cardiomyopathy; long noncoding RNAs; prevention and treatment strategies

Funding

  1. Zhengzhou University Overseas Virtual Research Institute Special Fund
  2. Henan Science and Technology Huimin Plan Fund [162207310005]
  3. Zhengzhou City Science and Technology Innovation Talents Training Program: Leading Talent Fund [10LJRC175]

Ask authors/readers for more resources

Diabetic cardiomyopathy (DCM) can cause extensive necrosis of the heart muscle by metabolic disorders and microangiopathy, with subclinical cardiac dysfunction, and eventually progress to heart failure, arrhythmia, and cardiogenic shock; severe patients may even die suddenly. Long noncoding RNAs (lncRNAs) are a class of nonprotein-coding RNAs longer than 200 nucleotides. They have critical roles in various biological processes, including gene expression regulation, genomic imprinting, nuclear-cytoplasmic trafficking, RNA splicing, and translational control. Recent studies indicated that lncRNAs extensively participate in the development of diverse cardiac diseases, such as cardiac ischaemia, hypertrophy, and heart failure. Little is known about lncRNA in DCM. In this review, we summarize the current literature on lncRNAs in DCM studies, aiming to provide new methods for DCM's future prevention and treatment strategies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available